PDCD1 and hepatocellular carcinoma: In the early phase I/II or phase II studies, the objective response rate (ORR) for advanced HCC people who were treated with the anti-PD-1 antibody of nivolumab or pembrolizumab has been shown to be 14%–20% with prolonged PFS and OS (14–16).